scholarly journals Clinical Significance of Preoperative Neutrophil Lymphocyte Ratio versus Platelet Lymphocyte Ratio in Patients with Small Cell Carcinoma of the Esophagus

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Ji-Feng Feng ◽  
Ying Huang ◽  
Qiang Zhao ◽  
Qi-Xun Chen
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Predictive Factor ◽  
Prognostic Significance ◽  
Small Cell ◽  
Survival Prediction ◽  
Carcinoma Of The Esophagus ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Platelet Lymphocyte Ratio

Recent studies have shown that the presence of systemic inflammation correlates with poor survival in various of cancers. The aim of this study was to determine the prognostic values of neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) in patients with small cell carcinoma of the esophagus (SCCE). Preoperative NLR and PLR were evaluated in 43 patients with SCCE from January 2001 to December 2010. The prognostic significance of both markers was then determined by both uni- and multivariate analytical methods. Receiver operating characteristic (ROC) curves were also plotted to verify the accuracy of NLR and PLR for survival prediction. Patients with PLR ≥150 had significantly poorer (relapse-free survival) RFS and (overall survival) OS compared to patients with PLR <150. However, RFS or OS did not differ according to NLR categories (<3.5 and ≥3.5). The areas under the curve (AUC) indicated that PLR was superior to NLR as a predictive factor. The results of the present study conclude that PLR is superior to NLR as a predictive factor in patients with SCCE.

Nomogram based on nutritional and inflammatory indicators for survival prediction of small cell carcinoma of the esophagus

Nutrition ◽  
2021 ◽  
Vol 84 ◽  
pp. 111086
Author(s):  
Hao Chen ◽  
Can-Tong Liu ◽  
Chao-Qun Hong ◽  
Ling-Yu Chu ◽  
Xin-Yi Huang ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Survival Prediction ◽  
Carcinoma Of The Esophagus

scholarly journals CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus

2021 ◽  
Vol 7 ◽  
Author(s):  
Kaikai Zhao ◽  
Lin Ma ◽  
Lei Feng ◽  
Zhaoqin Huang ◽  
Xiangjiao Meng ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Distant Metastasis ◽  
Proportional Hazards Model ◽  
Prognostic Significance ◽  
Small Cell ◽  
Cox Proportional Hazards Model ◽  
Tnm Stage ◽  
Carcinoma Of The Esophagus ◽  
T Stage

CD155/TIGIT overexpression has been detected in various human malignancies; however, its expression status in primary small cell carcinoma of the esophagus (PSCCE) and its prognostic significance remain unclear. In this study, we aimed to explore the expression and prognostic value of CD155 and TIGIT in PSCCE. We detected CD155 and TIGIT expression in 114 cases of PSCCE using immunohistochemistry (IHC) and evaluated their relationship with the clinicopathological characteristics and survival of the patients. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards model. Nomogram performance was assessed via the concordance index (C-index) and calibration plots. Decision curve analysis (DCA) was performed to evaluate the net benefit of the nomogram. We found that CD155 and TIGIT were overexpressed in PSCCE tissues, CD155 expression correlated positively with TIGIT (p &lt; 0.001) and was significantly associated with tumor size, T stage, distant metastasis, TNM stage, and Ki-67 score. TIGIT expression was also significantly associated with T stage, distant metastasis, and TNM stage. Patients with high CD155 and TIGIT expression had a significantly shorter overall survival (OS) and progression-free survival (PFS), while the multivariate model showed that CD155 expression and the therapeutic strategy are independent prognostic factors for PSCCE. In the validation step, OS was shown to be well-calibrated (C-index = 0.724), and a satisfactory clinical utility was proven by DCA. In conclusion, our findings revealed that CD155 and TIGIT are highly expressed in patients with PSCCE and are associated with shorter OS and PFS, supporting their role as prognostic biomarker.

Prognostic Value of Pretreatment Inflammatory Biomarkers in Primary Small Cell Carcinoma of the Esophagus

2019 ◽  
Author(s):  
Nan Wang ◽  
Xue Li ◽  
Hui Luo ◽  
Yanan Sun ◽  
Xiaoli Zheng ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Prognostic Value ◽  
Malignant Tumors ◽  
Univariate Analysis ◽  
Small Cell ◽  
Hazard Ratio ◽  
Inflammatory Biomarkers ◽  
Carcinoma Of The Esophagus ◽  
Lymphocyte Ratio

Abstract Background: Growing evidence indicates that several inflammatory biomarkers may predict survival in patients with malignant tumors. The aim of this study is to evaluate the prognostic value of pretreatment biomarkers in patients with primary small-cell carcinoma of the esophagus（PSCCE）. Methods: There were 73 PSCCE patients enrolled between January 2009 and December 2017 at the Affiliated Cancer Hospital of Zhengzhou University. The total lymphocyte counts (TLC), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) prior to anticancer therapy were collected as inflammation biomarkers. The cut-off value was determined by Receiver operating characteristic (ROC). The Kaplan–Meier method was utilized to analysis overall survival (OS). Cox proportional hazards regression was used to identify univariate and multivariate prognostic factors. Results: Univariate analysis showed that high NLR group(hazard ratio (HR) ＝1.685; 95% CI: 1.001–2.838; P＝0.047) and high PLR group (hazard ratio (HR) ＝1.716; 95% CI: 1.039–2.834; P＝0.033) were associated with poor OS, and TLC was not correlated with OS. On multivariate analysis, high PLR(hazard ratio (HR) ＝1.751; 95% CI: 1.042–2.945; P＝0.035) was an independent prognostic factor of unfavorable OS. Conclusions: Pre-treatment PLR and NLR are correlated with OS. These biomarkers are easily accessible, cost effective, and can serve as a marker to identify high-risk patients for further designing personalized treatment and predicting treatment outcomes.

scholarly journals MET-04 A case of Brain Metastases with repeated bleeding from Esophageal carcinoma

2020 ◽  
Vol 2 (Supplement_3) ◽  
pp. ii19-ii19
Author(s):  
Masataka Mikai ◽  
Mitsuyoshi Abe ◽  
Yo watanabe ◽  
Chie Nakada ◽  
Yutaka Huchinoue ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Brain Metastases ◽  
Esophageal Carcinoma ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Cerebral Hemorrhage ◽  
Small Cell ◽  
The Body ◽  
Metastatic Brain Tumor ◽  
Carcinoma Of The Esophagus

Abstract Brain metastases from esophageal cancer is rare and the incidence has been reported at approximately 5%. We report a case of brain metastases with repeated bleeding from Esophageal carcinoma. The case is a 76-year-old man. Three years ago he was diagnosed with small cell carcinoma of the esophagus by endoscopic biopsy. Metastasis was found only in the cervical lymph node, but the condition was stable by chemoradiotherapy and no metastases were found throughout the body before 1 month. He was admitted to the hospital because of a sudden convulsion, and CT scan revealed cerebral hemorrhage in the right frontal lobe. We performed conservative treatment, but rebleeding was observed from the same site repeatedly after 1 month and 2 months. Due to the influence of bleeding, it was difficult to distinguish cerebral hemorrhage from brain tumor by contrast MRI. After surgery, the cause of bleeding was diagnosed as metastatic brain tumor of esophageal small cell carcinoma. Postoperative radiation therapy was performed in another hospital, but rebleeding was observed 3 months after the operation. A reoperation was performed at another hospital, and a recurrence of metastatic brain tumor was diagnosed. In the case of highly malignant metastatic brain tumors, it was considered necessary to frequently follow the images.

Sign in / Sign up

Export Citation Format

Share Document